News

PipelineReview.com3h
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
Sanofi to pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics, a majority-owned subsidiary of ...
PipelineReview.com12h
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update
EMERYVILLE, CA, USA I July 31, 2025 I 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing ...
PipelineReview.com12h
Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson’s Disease
TAIPEI, Taiwan I August 1, 2025 I Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company focused on cellular energy restoration ...
PipelineReview.com12h
Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
EAST HANOVER, NJ, USA I July 31, 2025 I Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® ...